ClinicalTrials.gg
CompletedNCT04597918ALTIMETERUpdated Jun 15, 2026Results posted

A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab

A Phase 2 interventional study of Faricimab in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 23 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing faricimab in Macular Edema — 1 open to participants now, 3 under way, none of them phase 3. faricimab · Macular Edema.

Enrollment
10th of 13
99 · median 229
Started
2020
with 1 other
Phase 2
2 of 13
none open now
Registered
6th of 13
by date
Lead sponsor
8 of 13
Hoffmann-La Roche

Among the 13 studies testing faricimab in Macular Edema, this one is the 10th largest by enrollment, is one of 2 that started in 2020, is one of 2 in phase 2, and was the 6th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 13 studies testing faricimab in Macular Edema is open now. Recruiting first, the newest first:

About faricimab

faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing faricimab in Macular Edema, or all of them as a file.
02

Study summary

This is an exploratory, prospective, multicenter, open-label, single-arm, interventional, Phase IIb study designed to explore the associations over time between clinical assessments, multimodal imaging assessments, aqueous humor (AH) biomarker patterns, and genetic polymorphisms in participants with diabetic macular edema (DME) who are treated with faricimab.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of diabetes mellitus (Type 1 or Type 2), as defined by the World Health Organization (WHO) and/or American Diabetes Association
  • (HbA1c) ≤10%
  • Patients who are intravitreal (IVT) treatment-naïve in the study eye
  • Diabetic macular edema (DME) defined as macular thickening by spectral-domain optical coherence tomography (SD-OCT) involving the center of the macula. This inclusion criterion is to be assessed by the central reading center (CRC).
  • Decreased visual acuity (VA) attributable primarily to DME
  • Clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images to confirm diagnosis

Exclusion criteria

Exclusion Criteria:

  • Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1
  • Any known to any of the components in the faricimab injection, dilating eye drops, or any of the anesthetics and antimicrobial preparations used by the patient during the study
  • Any major illness or major surgical procedure within 1 month before the Day 1. One re-screening for this criterion is permitted
  • History of other diseases, other non-diabetic metabolic dysfunction, physical examination finding, historical or current clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the faricimab or that might affect interpretation of the results of the study or renders the patient at high-risk for treatment complications, in the opinion of the Investigator
  • Active cancer within the past 12 months prior to Day 1 except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of ≤6 and a stable prostate-specific antigen for >12 months
  • Stroke or myocardial infarction within 12 months prior to the Day 1. One re-screening for this criterion is permitted
  • Any febrile illness within 1 week prior to Day 1. One re-screening for this criterion is permitted
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab
  • Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis within 6 months prior to Day 1 or anticipated to require hemodialysis or peritoneal dialysis at any time during the study
  • Any condition resulting in a compromised immune system that is likely to impact the aqueous humor (AH) inflammatory biomarkers.
  • Patients who are currently enrolled in or have participated in any other clinical study involving an product or device, or in any other type of medical research, within 3 months or 5 half-lives prior to Day 1 and up to completion of the current study
  • Substance abuse occurring within 12 months prior to screening, in the Investigator's judgment
  • Use of systemic immunomodulatory treatments within 6 months or 5 half-lives prior to Day 1
  • Use of any systemic (including inhaled corticosteroids from inhalers used regularly, e.g., pulmonary disease, asthma, or seasonal allergy) within 1 month prior to Day 1
  • Any prior or concomitant systemic anti-VEGF treatment within 6 months or 5 half-lives prior to Day 1
  • Use of systemic medications known to be toxic to the lens, retina or optic nerve used during the 6-month period or 5 half-lives prior to Day 1 or likely need to be used
  • Received a blood transfusion within 3 months prior to the screening visit
  • Received any treatment that leads to within 6 months or 5 half-lives prior to Day 1

Ocular Exclusion Criteria for Study Eye:

  • High-risk PDR. This exclusion criterion is to be assessed by the CRC
  • Any history of or ongoing rubeosis iridis
  • Any panretinal photocoagulation or macular laser photocoagulation treatment received in the study eye prior to the screening visit or expected to be received between the screening visit and Day 1
  • Any history of treatment with anti-VEGF or any periocular or IVT corticosteroids in the study eye and no such treatment planned for the time between screening and Day 1
  • Any treatment for dry eye disease in the last month prior to Day 1. Lubricating eye drops and ointments are permitted.
  • Any treatment with anti-inflammatory eye drops within 1 month prior to Day 1
  • Any intraocular surgery within 3 months prior to Day 1 or any planned surgery during the study
  • Any glaucoma surgery/laser procedure involving the iris, trabecular meshwork, or ciliary body prior to the screening visit. Only iris surgery/laser might be allowed if they occurred more than 6 months prior to Day 1.
  • History of vitreoretinal surgery/pars plana vitrectomy, corneal transplant, or radiotherapy
  • Any active or suspected ocular or periocular infections on Day 1
  • Any presence of active intraocular inflammation on Day 1 or any history of intraocular inflammation
  • Any history of idiopathic, infectious, or noninfectious uveitis
  • Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision
  • Any current ocular condition or other causes of visual impairment for which, in the opinion of the Investigator, VA loss would not improve from resolution of macular edema

Ocular Exclusion Criteria for Fellow Eye:

  • Patient is currently receiving treatment with brolucizumab or bevacizumab in the non-study eye and is unwilling to switch to a protocol allowed non-study eye treatment during the study
  • Any previous treatment with Iluvien® or Retisert® in the non-study eye
  • Non-functioning non-study eye
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Faricimab

    Participants will receive 6 doses (one 6 mg faricimab intravitreal \[IVT\] injection every 28 days \[Q4W\]) starting at Day 1 and ending on the Day 140 visit. Participants will return for a safety follow-up visit (SFV) after ≥28 days and within \<35 days following their last study treatment.

    Drug: Faricimab

Interventions

  • A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).

    Also known as: VABYSMO™, RO6867461, RG7716

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye at Week 24

    The ETDRS DRSS score of each participant's study eye was assessed using ultra-wide field color fundus photography (UWF-CFP) taken by trained personnel at the study sites. Analysis of the fundus photographs was performed by the central reading center, and the percentage of participants with a ≥2-step improvement from baseline was summarized along with a two-sided 95% Clopper-Pearson exact confidence interval. Baseline was defined as the participant's last observation prior to initiation of study drug.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Adjusted Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) in the Study Eye at Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for visit, age (continuous), baseline BCVA (continuous), and region (US and Canada and the rest of the world). An unstructured covariance structure was used. In case of convergence issues with the model, an AR (1) covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM.

    Time frame: From Baseline to Week 24

  2. Adjusted Mean Change From Baseline in Central Subfield Thickness in the Study Eye at Week 24

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using Spectral Domain-Optical Coherence Tomography (SD-OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model was adjusted for visit, age (continuous), baseline CST (continuous), and region (US and Canada and the rest of the world). An unstructured covariance structure was used. In case of convergence issues with the model, an AR (1) covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM.

    Time frame: From Baseline to Week 24

  3. Median Time to First Absence of DME in the Study Eye During the Study

    An event was defined as the first absence of diabetic macular edema (DME) in the study eye, defined as first time reaching central subfield thickness (CST; ILM-RPE) \<305 microns, after baseline. Baseline was defined as the participant's last observation prior to initiation of study drug. The time to first absence of DME was a Kaplan-Meier estimate. The 95% confidence interval (CI) for the median was computed using the method of Brookmeyer and Crowley. Participants without an event and discontinued from treatment were censored at the last CST assessment.

    Time frame: From Baseline to Week 24

  4. Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Week 24

    The absence of intraretinal fluid (IRF) in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using Spectral Domain-Optical Coherence Tomography (SD-OCT). The percentage of participants with absence of IRF and a two-sided 95% Clopper-Pearson exact confidence interval are reported.

    Time frame: Week 24

  5. Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Week 24

    The absence of subretinal fluid (SRF) in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using Spectral Domain-Optical Coherence Tomography (SD-OCT). The percentage of participants with absence of SRF and a two-sided 95% Clopper-Pearson exact confidence interval are reported.

    Time frame: Week 24

07

Results

Posted Dec 1, 2023

Participant flow

A total of 99 patients were enrolled in the study at 23 sites in 7 countries.

Participant flow — Overall Study
MilestoneFaricimab
Started99
Completed89
Not completed10
Withdrew: Withdrawal by subject6
Withdrew: Lost to follow-up3
Withdrew: Death1

Outcome measures

PrimaryPercentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye at Week 24

The ETDRS DRSS score of each participant's study eye was assessed using ultra-wide field color fundus photography (UWF-CFP) taken by trained personnel at the study sites. Analysis of the fundus photographs was performed by the central reading center, and the percentage of participants with a ≥2-step improvement from baseline was summarized along with a two-sided 95% Clopper-Pearson exact confidence interval. Baseline was defined as the participant's last observation prior to initiation of study drug.

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye at Week 24
Percentage of participantsFaricimab
Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye at Week 2450.0 (37.2 to 62.8)
SecondaryAdjusted Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) in the Study Eye at Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for visit, age (continuous), baseline BCVA (continuous), and region (US and Canada and the rest of the world). An unstructured covariance structure was used. In case of convergence issues with the model, an AR (1) covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM.

Time frame:
From Baseline to Week 24
Reported as:
Mean · ETDRS Letters
Adjusted Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) in the Study Eye at Week 24
ETDRS LettersFaricimab
Adjusted Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) in the Study Eye at Week 249.2 (7.5 to 10.9)
SecondaryAdjusted Mean Change From Baseline in Central Subfield Thickness in the Study Eye at Week 24

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using Spectral Domain-Optical Coherence Tomography (SD-OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model was adjusted for visit, age (continuous), baseline CST (continuous), and region (US and Canada and the rest of the world). An unstructured covariance structure was used. In case of convergence issues with the model, an AR (1) covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM.

Time frame:
From Baseline to Week 24
Reported as:
Mean · microns
Adjusted Mean Change From Baseline in Central Subfield Thickness in the Study Eye at Week 24
micronsFaricimab
Adjusted Mean Change From Baseline in Central Subfield Thickness in the Study Eye at Week 24-200.2 (-214.1 to -186.2)
SecondaryMedian Time to First Absence of DME in the Study Eye During the Study

An event was defined as the first absence of diabetic macular edema (DME) in the study eye, defined as first time reaching central subfield thickness (CST; ILM-RPE) \<305 microns, after baseline. Baseline was defined as the participant's last observation prior to initiation of study drug. The time to first absence of DME was a Kaplan-Meier estimate. The 95% confidence interval (CI) for the median was computed using the method of Brookmeyer and Crowley. Participants without an event and discontinued from treatment were censored at the last CST assessment.

Time frame:
From Baseline to Week 24
Reported as:
Median · Weeks
Median Time to First Absence of DME in the Study Eye During the Study
WeeksFaricimab
Median Time to First Absence of DME in the Study Eye During the Study8.0 (8.0 to 12.0)
SecondaryPercentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Week 24

The absence of intraretinal fluid (IRF) in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using Spectral Domain-Optical Coherence Tomography (SD-OCT). The percentage of participants with absence of IRF and a two-sided 95% Clopper-Pearson exact confidence interval are reported.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Week 24
Percentage of participantsFaricimab
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Week 2426.1 (17.3 to 36.6)
SecondaryPercentage of Participants With Absence of Subretinal Fluid in the Study Eye at Week 24

The absence of subretinal fluid (SRF) in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using Spectral Domain-Optical Coherence Tomography (SD-OCT). The percentage of participants with absence of SRF and a two-sided 95% Clopper-Pearson exact confidence interval are reported.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Week 24
Percentage of participantsFaricimab
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Week 2498.9 (93.8 to 100.0)

Adverse events

Collected over From first dose of study drug until ≥28 days to <35 days after the last dose of study drug (up to 24 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Faricimab1/99 (1%)8/99 (8.1%)21/99 (21.2%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventFaricimab
Localised infectionInfections and infestations2/99
SepsisInfections and infestations2/99
COVID-19Infections and infestations1/99
CellulitisInfections and infestations1/99
Escherichia urinary tract infectionInfections and infestations1/99
OsteomyelitisInfections and infestations1/99
Acute myocardial infarctionCardiac disorders1/99
Coronary artery diseaseCardiac disorders1/99
Spinal operationSurgical and medical procedures1/99
Toe amputationSurgical and medical procedures1/99
Most frequent other events
Most frequent other events
EventFaricimab
COVID-19Infections and infestations7/99
Diabetic retinal oedemaEye disorders6/99
Retinal exudatesEye disorders5/99
HypertensionVascular disorders5/99

Baseline characteristics

There were 2 analysis populations in this study, the modified intent-to-treat (mITT; all patients enrolled in the study that received any amount of study treatment) and safety-evaluable (SAF; all patients enrolled in the study who received at least 1 injection of study treatment) populations. All 99 participants were included in both the mITT and SAF populations.

Age, Continuous
Age, Continuous(Years)Faricimab
Mean59.5 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Faricimab
Female38
Male61
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Faricimab
Hispanic or Latino25
Not Hispanic or Latino73
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Faricimab
Black or African American7
White86
Asian5
Unknown1
Region of Enrollment
Region of Enrollment(Participants)Faricimab
US and Canada62
Rest of the World37
Best-Corrected Visual Acuity (BCVA) in the Study Eye at Baseline
Best-Corrected Visual Acuity (BCVA) in the Study Eye at Baseline(ETDRS Letters)Faricimab
Mean62.5 ± 11.8
Central Subfield Thickness (CST) in the Study Eye at Baseline
Central Subfield Thickness (CST) in the Study Eye at Baseline(microns)Faricimab
Mean464.0 ± 149.5
08

Study locations

23 sites
  • Bascom Palmer Eye Institute
    Naples, Florida 34103, United States
  • Northwestern Medical Group/Northwestern University
    Chicago, Illinois 60611, United States
  • University Retina and Macula Associates, PC
    Oak Forest, Illinois 60452, United States
  • Raj K. Maturi, MD PC
    Indianapolis, Indiana 46290, United States
  • Cumberland Valley Retina PC
    Hagerstown, Maryland 21740, United States
  • The Retina Institute
    St Louis, Missouri 63128, United States
  • Long Is. Vitreoretinal Consult
    Great Neck, New York 11021, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Retina Res Institute of Texas
    Abilene, Texas 79606, United States
  • Austin Research Center for Retina
    Austin, Texas 78705, United States
  • Retina Consultants of Texas
    Houston, Texas 77030, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Centro Oftalmologico Dr. Charles S.A.
    Capital Federal, C1116, Argentina
  • Oftalmos
    Capital Federal, C1120AAN, Argentina
  • Vitreous Retina Macula Specialists of Toronto
    Etobicoke, Ontario M8X 2X3, Canada
  • Retina Institute of Ottawa
    Ottawa, Ontario K2B 7E9, Canada
  • Universitatsklinikum Tubingen
    Tübingen, 72076, Germany
  • Ospedale San Giuseppe
    Milan, Lombardy 20123, Italy
  • Irccs Ospedale San Raffaele
    Milan, Lombardy 20132, Italy
  • Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy
    Warsaw, 04-141, Poland
  • Gloucestershire Hospitals NHS Foundation Trust
    Gloucestershire, GL1 3NN, United Kingdom
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
  • Sunderland Eye Infirmary
    Sunderland, SR2 9HP, United Kingdom
09

References and documents

Publications

  • Schlottmann PG, Fawzi AA, Amador M, Dieckmann A, Gibson K, Glittenberg C, Jhaveri C, Kotak A, Mar F, Neubert A, Sheth VS, Souverain A, Titz B, Vazquez-Lombardi C, Wykoff CC, Ziemssen F, Vujosevic S. Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naive Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study. Ophthalmol Sci. 2026 Feb 26;6(5):101129. doi: 10.1016/j.xops.2026.101129. eCollection 2026 May. PubMed 42058170 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Dec 2022, 24 months.

Results were first posted in Dec 2023, 11 months after primary completion.

Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 24 months is above that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2020
First posted
Oct 22, 2020
StartActual
Nov 25, 2020
Primary completionActual
Dec 22, 2022
CompletionActual
Dec 22, 2022
Results first posted
Dec 1, 2023
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04597918
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 22, 2020
Start date
Nov 25, 2020
Primary completion
Dec 22, 2022
Completion
Dec 22, 2022
Results posted
Dec 1, 2023
Last update
Jun 15, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion